Randomized phase II study of SOX+B-mab versus SOX+C-mab in patients with previously untreated recurrent advanced colorectal cancer with wild-type KRAS (MCSGO-1107 study)
Số trang: 10
Loại file: pdf
Dung lượng: 1.24 MB
Lượt xem: 5
Lượt tải: 0
Xem trước 2 trang đầu tiên của tài liệu này:
Thông tin tài liệu:
Although chemotherapy for metastatic colorectal cancer (mCRC) has improved, the standard chemotherapy regimens for patients with RAS wild-type mCRC remain debated. This study aimed to compare S-1 and oxaliplatin (SOX) + bevacizumab (B-mab) with SOX + cetuximab (C-mab) in patients with previously untreated recurrent advanced CRC with wild-type KRAS.
Nội dung trích xuất từ tài liệu:
Randomized phase II study of SOX+B-mab versus SOX+C-mab in patients with previously untreated recurrent advanced colorectal cancer with wild-type KRAS (MCSGO-1107 study)
Nội dung trích xuất từ tài liệu:
Randomized phase II study of SOX+B-mab versus SOX+C-mab in patients with previously untreated recurrent advanced colorectal cancer with wild-type KRAS (MCSGO-1107 study)
Tìm kiếm theo từ khóa liên quan:
BMC Cancer Colorectal cancer Early tumor shrinkage Metastatic colorectal cancer Progressionfree survivalGợi ý tài liệu liên quan:
-
Differences between physician and patient preferences for cancer treatments: A systematic review
13 trang 166 0 0 -
6 trang 165 0 0
-
Immune checkpoint inhibitors and their impact on liver enzymes and attenuation
7 trang 138 0 0 -
2011–2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France
9 trang 107 0 0 -
12 trang 86 0 0
-
19 trang 72 0 0
-
17 trang 60 0 0
-
9 trang 35 0 0
-
11 trang 34 0 0
-
12 trang 33 0 0